Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • Offices
  • 200.Cravath

Cravath Publishes Summer 2026 Issue of Alumni Journal

Read More

News & Insights

DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®

October 04, 2024

On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.

The Cravath team is led by partners Cole DuMond and Daniel J. Cerqueira and includes associates Jason O. Rooindej and Alexander J.A. Burger on M&A matters; partner David J. Kappos, of counsel Kathryn‑Ann Stamm and associate Kenya Rowser on intellectual property matters; partner Nicholas A. Dorsey on financing matters; partner Christopher K. Fargo, of counsel Kiran Sheffrin and associate Josh Banafsheha on tax matters; and partner George E. Zobitz and of counsel Alexander Gerten on financial restructuring and reorganization matters. Abby Baskin also worked on M&A matters.

Related Practices & Industries

  • Corporate
  • Mergers and Acquisitions
  • IP and Strategic Tech Transactions
  • Capital Markets
  • Banking and Credit
  • Tax
  • Financial Restructuring and Reorganization
  • Private Equity
  • Financial Services and Insurance
  • Healthcare and Life Sciences

People

Photo
Name
Cole DuMond
Title
Corporate
Title
Partner
Email
cdumond@cravath.com
Phone
+1-212-474-1216
vCard
Download vCard

    Education

    • J.D., 2016, University of Pennsylvania Law School
      cum laude
    • B.S., 2013, Cornell University

    Admitted In

    • New York
    Photo
    Name
    Daniel J. Cerqueira
    Title
    Corporate
    Title
    Partner
    Email
    dcerqueira@cravath.com
    Phone
    +1-212-474-1156
    vCard
    Download vCard

      Education

      • J.D., 2013, Harvard Law School
        magna cum laude
      • B.A., 2010, Cornell University
        Phi Beta Kappa

      Admitted In

      • New York
      Photo
      Name
      David J. Kappos
      Title
      Corporate
      Title
      Partner
      Email
      dkappos@cravath.com
      Phone
      +1-212-474-1168
      vCard
      Download vCard

        Education

        • J.D., 1990, University of California, Berkeley, School of Law
        • B.S., 1983, University of California, Davis
          summa cum laude

        Admitted In

        • New York
        • California
        • District of Columbia
        Photo
        Name
        Nicholas A. Dorsey
        Title
        Corporate
        Title
        Partner
        Email
        ndorsey@cravath.com
        Phone
        +1-212-474-1764
        vCard
        Download vCard

          Education

          • J.D., 2009, Cornell Law School
            Order of the Coif, summa cum laude
          • M.Acc., 2006, Case Western Reserve University
            summa cum laude
          • B.S., 2006, Case Western Reserve University
            summa cum laude

          Admitted In

          • New York
          Photo
          Name
          Christopher K. Fargo
          Title
          Tax
          Title
          Partner
          Email
          cfargo@cravath.com
          Phone
          +1-212-474-1236
          vCard
          Download vCard

            Education

            • J.D., 2006, Columbia Law School
              Harlan Fiske Stone; Michael Lynne Scholar
            • B.A., 2003, Boston College
              Honors Program, cum laude

            Admitted In

            • New York
            Name
            George E. Zobitz
            Title
            Corporate
            Title
            Partner
            Email
            jzobitz@cravath.com
            Phone
            +1-212-474-1996
            vCard
            Download vCard

              Education

              • J.D., 1995, New York University School of Law
                with Honors, cum laude
              • B.A., 1991, Franklin & Marshall College

              Admitted In

              • New York
              Photo
              Name
              Kathryn-Ann Stamm
              Title
              Corporate
              Title
              Of Counsel
              Email
              kstamm@cravath.com
              Phone
              +1-212-474-1979
              vCard
              Download vCard

                Education

                • J.D., 2016, Cornell Law School
                • LL.M., 2016, City University of Hong Kong
                • Master II, 2016, University Paris 1 Pantheon-Sorbonne
                • Master I, 2013, University Paris 1 Pantheon-Sorbonne
                • LL.B., 2013, University Paris 1 Pantheon-Sorbonne
                • LL.B., 2013, King's College London
                  First Class Honors.

                Admitted In

                • New York

                Related News & Insights

                Deals & Cases

                November 05, 2026

                Liberty Media’s Acquisition of High‑Vote Series B Common Stock from John C. Malone‑Related Entities

                On November 5, 2026, Liberty Media Corporation (“Liberty Media”) announced that it has acquired all shares of Liberty Media’s high‑vote Series B common stock held by certain entities related to John C. Malone (the “Malone Holders”) in exchange for shares of Liberty Media’s low‑vote Series A common stock and shares of Liberty Media’s non‑voting Series C common stock. As a result of the transaction, the Malone Holders’ aggregate voting power in Liberty Media declined to approximately 3%, and no holder of Liberty Media common stock holds more than 9% of Liberty Media’s voting power, in each case, based on Liberty Media’s outstanding common stock as of October 30, 2026. The transaction was negotiated and approved by a special committee (the “Special Committee”) of Liberty Media’s board of directors consisting solely of disinterested and independent directors for purposes of Nevada law, advised by its own independent financial and legal advisors. Cravath is representing the Special Committee in connection with the transaction.

                Deals & Cases

                October 29, 2026

                ADT’s $15.3 Billion Acquisition by Thrive Holdings

                On October 29, 2026, ADT Inc. (“ADT”), a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., and Thrive Holdings, a permanent capital holding company focused on investing in established businesses and advancing their capabilities through technology, announced a definitive agreement under which Thrive Holdings will acquire ADT in an all‑cash transaction. The agreement values ADT at approximately $7.6 billion in equity value and $15.3 billion in enterprise value. Under the terms of the agreement, which ADT’s Board of Directors unanimously approved, ADT stockholders will receive $10.00 per share in cash upon completion. Following completion, ADT will become privately held and its common stock will cease trading on the New York Stock Exchange. Cravath is representing ADT in connection with the transaction.

                Deals & Cases

                August 31, 2026

                Aon’s $17 Billion Acquisition of USI

                On August 31, 2026, Aon, a leading global professional services firm, announced the signing of a definitive agreement to acquire USI, a leading provider of property & casualty, employee benefit, personal risk and retirement solutions for the middle market and the tenth largest U.S. insurance broker, from KKR and other shareholders for a total purchase price of $17 billion. Aon expects to fund the transaction, as well as related transaction expenses and other costs, with new debt raised across a range of maturities, subject to market conditions. The transaction has been unanimously approved by the Board of Directors of Aon and the Board of Directors of USI. Cravath is representing Aon in connection with the transaction.

                Deals & Cases

                March 31, 2026

                Biogen’s $5.6 Billion Acquisition of Apellis

                On March 31, 2026, Biogen Inc. and Apellis Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. Cravath is representing Biogen in connection with the transaction.

                Cravath Bicentennial

                Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

                Explore

                Cravath, Swaine & Moore LLP Logo
                • CONTACT US
                • OUR STORY
                • ALUMNI PORTAL
                • DISCLAIMERS & NOTICES

                Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.